IN2013MU02133A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02133A
IN2013MU02133A IN2133MU2013A IN2013MU02133A IN 2013MU02133 A IN2013MU02133 A IN 2013MU02133A IN 2133MU2013 A IN2133MU2013 A IN 2133MU2013A IN 2013MU02133 A IN2013MU02133 A IN 2013MU02133A
Authority
IN
India
Prior art keywords
acetoxyandrosta
diene
pharmaceutically acceptable
acceptable salt
abiraterone acetate
Prior art date
Application number
Inventor
Rajamannar Thennati
Rajeev Budhdev Rehani
Nischalkumar Vinodbhai Patel
Riteshkumar Rajnikant Kansara
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Priority to JP2016522965A priority Critical patent/JP2016527213A/en
Priority to PCT/IN2014/000420 priority patent/WO2014207762A1/en
Priority to EP14816900.6A priority patent/EP3013844A4/en
Priority to US14/392,210 priority patent/US20160176915A1/en
Priority to IN2133MU2013 priority patent/IN2013MU02133A/en
Publication of IN2013MU02133A publication Critical patent/IN2013MU02133A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to improvement in the process of preparation of abiraterone acetate or a pharmaceutically acceptable salt thereof wherein the improvement comprises purifying the crude 3-?-acetoxyandrosta-5,16-diene-17-yl trifluoromethane sulphonate by crystallization from a solvent to obtain acetoxyandrosta-5,16-diene-17-yl trifluoromethane sulphonate as a crystalline solid and converting it to abiraterone acetate or pharmaceutically acceptable salt thereof.
IN2133MU2013 2013-06-24 2014-06-24 IN2013MU02133A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2016522965A JP2016527213A (en) 2013-06-24 2014-06-24 Method for producing abiraterone acetate
PCT/IN2014/000420 WO2014207762A1 (en) 2013-06-24 2014-06-24 Process for preparation of abiraterone acetate
EP14816900.6A EP3013844A4 (en) 2013-06-24 2014-06-24 Process for preparation of abiraterone acetate
US14/392,210 US20160176915A1 (en) 2013-06-24 2014-06-24 Process for preparation of abiraterone acetate
IN2133MU2013 IN2013MU02133A (en) 2013-06-24 2014-06-24

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2133MU2013 IN2013MU02133A (en) 2013-06-24 2014-06-24

Publications (1)

Publication Number Publication Date
IN2013MU02133A true IN2013MU02133A (en) 2015-06-05

Family

ID=52141189

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2133MU2013 IN2013MU02133A (en) 2013-06-24 2014-06-24

Country Status (5)

Country Link
US (1) US20160176915A1 (en)
EP (1) EP3013844A4 (en)
JP (1) JP2016527213A (en)
IN (1) IN2013MU02133A (en)
WO (1) WO2014207762A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108948120A (en) * 2018-07-07 2018-12-07 张正光 A kind of preparation method of Abiraterone acetate intermediate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69327096T2 (en) * 1992-03-31 2000-06-21 Btg Int Ltd 17-SUBSTITUTED STEROIDS, USED IN CANCER TREATMENT
DK1781683T3 (en) * 2004-08-24 2012-02-06 Btg Int Ltd Process for the preparation of 17-vinyl triflates as semi-finished products
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
CA2890589A1 (en) * 2012-11-09 2014-05-15 Synthon Bv Process for making abiraterone-3-acetate
EP2917226A1 (en) * 2012-11-09 2015-09-16 Synthon BV Process for making the 17-triflate intermediate of abiraterone-3-acetate
US9650410B2 (en) * 2013-07-29 2017-05-16 Industriale Chimica S.R.L. Process for the preparation of abiraterone and abiraterone acetate
WO2015014686A1 (en) * 2013-07-29 2015-02-05 Industriale Chimica S.R.L. Process for the preparation of abiraterone or abiraterone acetate

Also Published As

Publication number Publication date
US20160176915A1 (en) 2016-06-23
WO2014207762A1 (en) 2014-12-31
JP2016527213A (en) 2016-09-08
EP3013844A1 (en) 2016-05-04
EP3013844A4 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
IN2015KN00262A (en)
WO2011119004A3 (en) Method of producing d-psicose crystals
SG10201808624VA (en) Polymorphs of selinexor
WO2014072961A3 (en) Polymorphic forms of suvoroxant
EP2999688A4 (en) Process to prepare levulinic acid
HK1220965A1 (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same abexinostate
EP2970083A4 (en) Process to prepare levulinic acid
WO2012015999A3 (en) Process for the preparation of imatinib mesylate
WO2015102022A3 (en) An improved process for the preparation of abiraterone acetate
WO2013128379A3 (en) Crystalline polymorphic forms of linagliptin
UY33511A (en) PROCEDURE FOR OBTAINING THE CRYSTAL FORM II OF FEBUXOSTAT
WO2014141294A3 (en) An improved process for the synthesis of melphalan and the hydrochloride salt
EP2968255A4 (en) Process for making hmf from sugars with reduced byproduct formation, and improved stability hmf compositions
WO2014118606A3 (en) A novel process for the preparation of silodosin
WO2013072938A3 (en) Process for the preparation of roflumilast
IL245260B (en) A crystalline anhydrous form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
WO2015087343A3 (en) An improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof
WO2014195977A3 (en) Novel polymorphs of vismodegib
IN2013MU02133A (en)
WO2012159981A3 (en) PROCESS FOR THE PREPARATION OF α-SUBSTITUTED KETONES AND THEIR APPLICATION IN SYNTHESIS OF PHARMACEUTICALLY ACTIVE COMPOUNDS
UY33510A (en) PROCEDURE FOR OBTAINING THE CRYSTAL FORM A OF FEBUXOSTAT
WO2017029642A3 (en) Novel polymorphs of dolutegravir and salts thereof
IN2013MU03508A (en)
WO2015001568A3 (en) Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof
WO2015104602A3 (en) A process for the preparation of anagliptin and its intermediates thereof